Blocking Two-Pore Domain Potassium Channel TREK-1 Inhibits the Activation of A1-Like Reactive Astrocyte Through the NF-κB Signaling Pathway in a Rat Model of Major Depressive Disorder
Authors:
Open Access
- 20 January 2023
- journal article
- research article
- Published by Springer Nature in Neurochemical Research
- Vol. 48 (6) , 1737-1754
Abstract
Major depressive disorder (MDD) refers to a widespread psychiatric disorder. Astrocytes play a pivotal role in regulating inflammation which is a well-acknowledged key component in depression pathogenesis. However, the effects of the neuroinflammation-inducing A1-like astrocytes on MDD are still unknown. TWIK-related K+ channel 1 (TREK-1) has been demonstrated to regulate the action of antidepressants. Nevertheless, its mechanisms and effects on A1-like astrocyte stimulation in MDD are not clear. Therefore, we conducted in vivo and in vitro experiments using TREK-1 specific inhibitor spadin. In vivo, rats were subjected to a 6-week chronic unpredictable mild stress (CUMS) followed by spadin treatment. Behavioral tests were employed to surveil depressive-like behaviors. Hippocampal proteomic analysis was carried out with the purpose of identifying differentially expressed proteins after CUMS and spadin treatments. In vitro, astrocyte-conditioned medium and spadin were used to treat rat astrocyte cell line. The activated microglia, inflammatory factors, A1 astrocyte markers, and activated nuclear factor kappa B (NF-κB) pathway were later analyzed using immunofluorescence, western blot, and RT-qPCR. Our findings indicated that blockage of TREK-1 reduced CUMS-induced depressive-like behavior in rats, inhibited the microglial stimulation, reduced inflammatory factor levels, and suppressed the activation of A1-like reactive astrocytes in the hippocampus. We also verified that the suppression of A1-like astrocytes by spadin necessitated the NF-κB pathway. According to the findings, blocking TREK-1 inhibited the activation of A1-like reactive astrocytes via the NF-κB signaling pathway in MDD. Our study preliminarily identifies a novel antidepressant mechanism of TREK-1 action and provides a therapeutic path for MDD.Keywords
This publication has 47 references indexed in Scilit:
- Pathogenesis of depression: Insights from human and rodent studiesNeuroscience, 2016
- Mixing and matching TREK/TRAAK subunits generate heterodimeric K 2P channels with unique propertiesProceedings of the National Academy of Sciences, 2016
- TREK1 channel blockade induces an antidepressant-like response synergizing with 5-HT1A receptor signalingEuropean Neuropsychopharmacology, 2015
- NFκB-Activated Astroglial Release of Complement C3 Compromises Neuronal Morphology and Function Associated with Alzheimer’s DiseaseNeuron, 2015
- Functional regeneration beyond the glial scarExperimental Neurology, 2014
- A disulphide-linked heterodimer of TWIK-1 and TREK-1 mediates passive conductance in astrocytesNature Communications, 2014
- Electrophysiology and pharmacology of tandem domain potassium channel TREK-1 related BDNF synthesis in rat astrocytesNaunyn-Schmiedeberg's Archives of Pharmacology, 2014
- Spadin, a Sortilin-Derived Peptide, Targeting Rodent TREK-1 Channels: A New Concept in the Antidepressant Drug DesignPLOS Biology, 2010
- The molecular neurobiology of depressionNature, 2008
- Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotypeNature Neuroscience, 2006